Investors sold shares of Allergan PLC (NYSE:AGN) on strength during trading on Tuesday. $114.90 million flowed into the stock on the tick-up and $159.81 million flowed out of the stock on the tick-down, for a money net flow of $44.91 million out of the stock. Of all stocks tracked, Allergan PLC had the 0th highest net out-flow for the day. Allergan PLC traded up $1.10 for the day and closed at $248.95

AGN has been the subject of a number of analyst reports. S&P Equity Research reiterated a “buy” rating on shares of Allergan PLC in a report on Tuesday, April 12th. Piper Jaffray Cos. reiterated a “cautious” rating and set a $236.00 price objective (down from $238.00) on shares of Allergan PLC in a report on Wednesday, May 11th. Guggenheim began coverage on shares of Allergan PLC in a report on Monday, April 18th. They set a “neutral” rating for the company. Goldman Sachs Group Inc. restated a “buy” rating and set a $275.00 price target on shares of Allergan PLC in a report on Monday, April 18th. Finally, Deutsche Bank AG restated a “buy” rating on shares of Allergan PLC in a report on Monday, April 18th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $307.70.

The firm has a 50 day moving average price of $239.07 and a 200-day moving average price of $254.12. The stock has a market cap of $98.47 billion and a price-to-earnings ratio of 22.28.

Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 10th. The company reported $3.04 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.01. The firm had revenue of $3.80 billion for the quarter, compared to the consensus estimate of $3.97 billion. The business’s quarterly revenue was up 48.1% on a year-over-year basis. On average, equities research analysts forecast that Allergan PLC will post $14.14 earnings per share for the current fiscal year.

In other news, Director Nesli Basgoz sold 459 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total transaction of $103,320.90. Following the sale, the director now owns 5,242 shares of the company’s stock, valued at approximately $1,179,974.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Maria Teresa Hilado purchased 661 shares of the company’s stock in a transaction dated Thursday, June 2nd. The shares were bought at an average cost of $241.57 per share, for a total transaction of $159,677.77. Following the acquisition, the chief financial officer now owns 11,957 shares in the company, valued at $2,888,452.49. The disclosure for this purchase can be found here.

Several hedge funds recently made changes to their positions in the stock. Utah Retirement Systems increased its stake in shares of Allergan PLC by 0.3% in the fourth quarter. Utah Retirement Systems now owns 70,461 shares of the company’s stock worth $22,019,000 after buying an additional 200 shares during the last quarter. State of Tennessee Treasury Department increased its stake in shares of Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock worth $145,669,000 after buying an additional 268,357 shares during the last quarter. Employees Retirement System of Texas increased its stake in shares of Allergan PLC by 265.5% in the fourth quarter. Employees Retirement System of Texas now owns 148,258 shares of the company’s stock worth $46,331,000 after buying an additional 107,700 shares during the last quarter. Affinity Investment Advisors LLC increased its stake in shares of Allergan PLC by 0.5% in the fourth quarter. Affinity Investment Advisors LLC now owns 64,560 shares of the company’s stock worth $20,175,000 after buying an additional 299 shares during the last quarter. Finally, Edgewood Management LLC increased its stake in shares of Allergan PLC by 10.9% in the fourth quarter. Edgewood Management LLC now owns 1,459,579 shares of the company’s stock worth $456,118,000 after buying an additional 143,657 shares during the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.